Cita APA

Sepulveda-Sanchez, J., Vaz, M., Balana, C., Gil-Gil, M., Reynes, G., Gallego, O., . . . Hernandez-Lain, A. (2017). Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.

Citación estilo Chicago

Sepulveda-Sanchez, JM, et al. Phase II Trial of Dacomitinib, a Pan-human EGFR Tyrosine Kinase Inhibitor, in Recurrent Glioblastoma Patients With EGFR Amplification. 2017.

Cita MLA

Sepulveda-Sanchez, JM, et al. Phase II Trial of Dacomitinib, a Pan-human EGFR Tyrosine Kinase Inhibitor, in Recurrent Glioblastoma Patients With EGFR Amplification. 2017.